26th week of 2014 patent applcation highlights part 47 |
Patent application number | Title | Published |
20140178402 | PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9 - The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. | 2014-06-26 |
20140178403 | METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST - Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | 2014-06-26 |
20140178404 | USE OF NEUREGULIN-4 FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND NECROTIZING ENTEROCOLITIS - The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4. | 2014-06-26 |
20140178405 | MONOMERIC VHH DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, IMMUNISATION METHOD, ROTAVIRUS DETECTION METHOD, COMPOSITION, PREVENTION AND TREATMENT METHODS FOR ROTAVIRUS INFECTIONS - Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus. | 2014-06-26 |
20140178406 | USE OF GOAT SERUM FOR VETERINARY TREATMENT - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 2014-06-26 |
20140178407 | Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody. | 2014-06-26 |
20140178408 | METHOD OF PRODUCING AN ANTIBODY - The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor γ-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model. | 2014-06-26 |
20140178409 | SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME - As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC. | 2014-06-26 |
20140178410 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE - The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26. | 2014-06-26 |
20140178411 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES - Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided. | 2014-06-26 |
20140178412 | COMPOUNDS AND METHODS FOR THE TREATMENT OF EGFR POSITIVE DISEASES - Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided. | 2014-06-26 |
20140178413 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES - Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided. | 2014-06-26 |
20140178414 | MAYTANSINOID DERIVATIVES - Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided. | 2014-06-26 |
20140178415 | MAYTANSINOID DERIVATIVES - Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided. | 2014-06-26 |
20140178416 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 2014-06-26 |
20140178417 | METHODS FOR TREATING CANCER USING AN IMMUNOTOXIN - The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotixin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of | 2014-06-26 |
20140178418 | Breast Cancer Vaccine - Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human α-lactalbumin. | 2014-06-26 |
20140178419 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS) - The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection. | 2014-06-26 |
20140178420 | Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides - The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease. | 2014-06-26 |
20140178421 | Use of Native Peptides and Their Optimized Derivatives For Vaccination - The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides. | 2014-06-26 |
20140178422 | PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM - Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described. | 2014-06-26 |
20140178423 | NOVEL COMPOSITIONS AND METHODS - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 2014-06-26 |
20140178424 | IMMUNOGENIC COMPOSITION - The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of | 2014-06-26 |
20140178425 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 2014-06-26 |
20140178426 | Nucleic Acid Composition and Methods of Eliciting an Immune Response Using the Same - The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV. | 2014-06-26 |
20140178427 | TOTAL POLYSACCHARIDES OF RADIX ISATIDIS AND THEIR FRACTIONS, AND USES THEREOF AS VACCINE ADJUVANTS - The present invention pertains to medicinal technical field, relates to a Radix isatidis total polysaccharide and fractions thereof and their uses as vaccine adjuvant. Specifically, it relates to a Radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction extracted from Chinese medicinal material Radix isatidis, and to their uses as vaccine adjuvant or uses in manufacture of vaccine composition. The present invention further relates to a vaccine adjuvant and vaccine preparation comprising the above Radix isatidis total polysaccharide or polysaccharide fraction, a method for preparing antibody, and a method for immunization or inoculation. The Radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction of the present invention all can be used as adjuvant for attenuated vaccines, protein vaccines, DNA vaccines or polypeptide vaccines. | 2014-06-26 |
20140178428 | QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS CONTAINING SQUALENE - Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions. | 2014-06-26 |
20140178429 | Vaccines Including Antigen From Four Strains of Influenza Virus - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 2014-06-26 |
20140178430 | IDNA VACCINES AND METHODS FOR USING THE SAME - Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus. | 2014-06-26 |
20140178431 | LIPID AND NITROUS OXIDE COMBINATION AS ADJUVANT FOR THE ENHANCEMENT OF THE EFFICACY OF VACCINES - The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. | 2014-06-26 |
20140178432 | PRODUCTION OF DENSE BODIES (DB) FROM HCMV-INFECTED CELLS - The invention relates to the production of dense bodies (DB) and to a pharmaceutical composition containing DB. | 2014-06-26 |
20140178433 | LEPTOSPIRA WITH INCREASED ANTIGENIC MASS - The antigenic mass of | 2014-06-26 |
20140178434 | METHOD AND COMPOSITIONS - A method of preparing a compound of formula (III): | 2014-06-26 |
20140178435 | VACCINE COMPRISING INACTIVATED CELLS OF HAEMOPHILUS PARASUIS BACTERIA OF SEROTYPE 5 - The present invention pertains to the use of | 2014-06-26 |
20140178436 | METHOD FOR INCREASING ETEC CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND PRODUCTS OBTAINABLE THEREOF - A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods. | 2014-06-26 |
20140178437 | USE OF A FOOD ADDITIVE BASED ON AT LEAST ONE PHYTONUTRIENT FOR STIMULATING VACCINE IMMUNITY AGAINST APICOMPLEXA IN ANIMALS - The invention relates to the use of a food additive comprising at least one phytonutrient in order to stimulate vaccine immunity against | 2014-06-26 |
20140178438 | INDIVIDUALIZED VACCINES FOR CANCER - The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method. | 2014-06-26 |
20140178439 | CAPTURE OF PATHOGENIC AND NON-PATHOGENIC BIOPOLYMERS AND BIOPARTICLES - A method of preparing a capturing agent for a selected biopolymer or bioparticle, includes the steps of:
| 2014-06-26 |
20140178440 | TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF - Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects. | 2014-06-26 |
20140178442 | COMPOSITIONS AND ARTICLES HAVING A PARENT FRAGRANCE AND MICROCAPSULES ENCAPSULATING A NON-PARENT FRAGRANCE - A composition having a parent fragrance and microcapsules encapsulating another fragrance; and methods related thereto. | 2014-06-26 |
20140178443 | Strip For The Delivery Of An Oral Care Active And Methods For Applying Oral Care Actives - A strip of material for the delivery of an oral care active is disclosed. The strip of material includes a structural elastic-like film backing layer including a strainable network having a first region and a second region formed of substantially the same material composition, the first region providing a first, elastic-like resistive force to an applied axial elongation, and the second region providing a second distinctive resistive force to further applied axial elongation, thereby providing at least two stages of resistive forces in use; and an oral care composition disposed on the film, the oral care composition including an oral care active. | 2014-06-26 |
20140178444 | LONG CHAIN GLYCOLIPIDS USEFUL TO AVOID PERISHING OR MICROBIAL CONTAMINATION OF MATERIALS - The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. | 2014-06-26 |
20140178445 | STABLE THREE-PHASED EMULSIONS - Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase comprising water and an emulsifier comprising a hydrophilic-lipophilic balance (HLB) value of 10 to 19; and a water-in-oil inner phase comprising water, an oil, and a silicone polyglucoside containing emulsifier, wherein the water phase of the water-in-oil inner phase does not include a salt. | 2014-06-26 |
20140178446 | HEMOSTATIC AGENT FOR TOPICAL AND INTERNAL USE - This invention relates to deployable hemostatic materials comprising chitosan fibers. The hemostatic materials are suitable for use in sealing or controlling active bleeding from artery and vein lacerations and punctures, and for controlling oozing from tissue. | 2014-06-26 |
20140178447 | REDUCTION OF BIOFILMS ON MEDICAL DEVICES - Disclosed herein are methods and compositions for rendering medical devices and other surfaces biofilm resistant by the use of a coating composition comprising a combination of one or more antimicrobial agent, one or more anti-inflammatory agent, optionally a releasing agent, optionally decandediol, and a lubricious matrix system comprising a biomedical polymer. In certain embodiments said coating composition is adhered to the device or surface by a coating comprising urethane and silicone adhesives. | 2014-06-26 |
20140178448 | CONTINUOUS CULTURING DEVICE - A continuous device for culturing mammalian cells in a three-dimensional structure for the transplantation or implantation in vivo is described. The culturing device comprises (a) a scaffold formed by a matrix of interconnected growth surfaces spaced at regular intervals and (b) a fluid distribution means at the inlet and the exit of the growth areas. The device is particularly useful for culturing bone cells for dental implants or bone reconstruction. | 2014-06-26 |
20140178449 | METHODS FOR TREATING PARKINSON'S DISEASE - Methods for restoring normal patterns of activity in a subject suffering from Parkinson's Disease are disclosed that include administering an effective steady state concentration of a dopamine modulating compound continuously for a prolonged period of time such that normal patterns of activity are substantially restored in the subject. | 2014-06-26 |
20140178450 | Compositions and Methods for Tissue Repair with Extracellular Matrices - Described herein are compositions comprising decellularized extracellular matrix derived from skeletal muscle or other suitable tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damage, ischemic, ulcer cells, tissues or organs in a subject preferably a human, with diseases, such as PAD and CLI, using a decellularized extracellular matrix of the invention are provided. Methods of preparing culture surfaces and culturing cells with absorbed decellularized extracellular matrix are provided. | 2014-06-26 |
20140178451 | ACTIVATORS OF CXCR3 FOR THE TREATMENT OF ANGIOPATHIES OF THE EYE - The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof. | 2014-06-26 |
20140178452 | Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device - Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque. | 2014-06-26 |
20140178453 | DEVICES AND METHODS FOR THE REGENERATION OF BONY DEFECTS - This invention relates to methods for producing a composite bone graft material that can regenerate bony defects in the body. The invention further relates to methods that allow for the production of bioactive glass particles used in the composite that have been surface treated to allow for the production of a highly porous composite that can hold significant amounts of body fluid or other molecules that will aid in the regenerative process. The method of surface treatment allows for the manufacture of a suitable implantable composite while retaining the unique osteostimulative properties that are associated with bioactive glass particles. | 2014-06-26 |
20140178454 | Coating Comprising an Amorphous Primer Layer and a Semi-Crystalline Reservoir Layer - The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same. | 2014-06-26 |
20140178455 | Gradient Porous Scaffolds - The present invention provides gradient porous scaffolds for bone regeneration and osteochondral defect repair, methods for making such gradient porous scaffolds, and methods for using the gradient porous scaffolds. | 2014-06-26 |
20140178456 | METHODS AND COMPOSITIONS FOR TREATING TYPE 2 DIABETES AND RELATED CONDITIONS - In some embodiments, there are provided methods and compositions for treating, preventing, or delaying the onset of type 2 diabetes and related disorders. The methods comprise administering a sustained release composition comprising a peroxisome proliferator-activated receptor (PPAR) agonist subcutaneously in a localized area of the subject. Slow release of the PPAR agonist in situ enhances the metabolic activity of subcutaneous adipose tissue, resulting in an increased ability of the tissue to clear excess glucose and lipid from the blood stream, while minimizing adverse side-effects of the agonist. | 2014-06-26 |
20140178457 | BINDER AND PROCESS FOR PRODUCING FABRICS CONTAINING CYCLODEXTRINS FIXED BY SAID BINDER - The application concerns a Binder (comprising sulfamic acid, ammonium sulfamate and ammonium sulfate) and process of production of fabrics containing cyclodextrins fixed to the binder. The technology allows fixing a binder to natural, synthetic or artificial fibers, and, by means of a thermal processes, to fix cyclodextrins to the same binder, giving rise to fabrics suitable to incorporate active principles and to release them along with time. Peculiar characteristics of the binder are its abilities to interact with several types of fabric, independently of their composition, and with several types of cyclodextrin. Other peculiarities of embodiments are: the ability to produce functionalized fabrics, adapted to be weighted with desired molecules and release them gradually along time, with a process that does not alter the original characteristics of the fabric; the possibility of repeating several times the weighting of such molecules, so as to be able to define such fabrics as “reloadable” or “rechargeable.” | 2014-06-26 |
20140178458 | MEDICINAL SKIN PROTECTION COMPOSITION WITH AN ACTIVE INGREDIENT COMBINATION WHICH IMPROVES THE SKIN BARRIER - A medicinal skin protection composition is disclosed with an active ingredient combination that specifically serves to care for aging skin that is exposed to difficult environmental conditions. The active ingredient combination obligatorily includes the components almond oil, linseed oil fatty acids, amino acids, and creatine. The medicinal skin protection composition can be used for aging skin in the form of creams, lotions etc., and also for a variety of incontinence articles, such as sanitary towels or nappies. | 2014-06-26 |
20140178459 | COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF HORMONES AND OTHER MEDICINAL AGENTS - The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility. | 2014-06-26 |
20140178460 | Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts. | 2014-06-26 |
20140178461 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF LUNG AND BRAIN CANCER AND PRECANCEROUS CONDITIONS THEREOF - Novel compounds and pharmaceutical compositions thereof administered by the respiratory route for prevention and/or treatment of lung and brain cancer and precancerous conditions thereof. | 2014-06-26 |
20140178462 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS - An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients. | 2014-06-26 |
20140178463 | COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. | 2014-06-26 |
20140178464 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 2014-06-26 |
20140178465 | METHOD AND USE OF NANO-SCALE DEVICES FOR REDUCTION OF TISSUE INJURY IN ISCHEMIC AND REPERFUSION INJURY - A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue. | 2014-06-26 |
20140178466 | Steroidal Compositions - Provided herein are steroid containing composition suitable for providing therapeutically effective amount of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 2014-06-26 |
20140178467 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism. | 2014-06-26 |
20140178468 | MULTIPARTICULATE EXTENDED-RELEASE COMPOSITION OF MESALAMINE - The present invention relates to a multiparticulate extended-release pharmaceutical composition of mesalamine comprising a) an inert core, b) an active ingredient layer and one or more pharmaceutically acceptable excipients, c) an inner coating layer comprising a water-insoluble cellulose derivative, and d) an outer coating layer comprising an enteric polymer. | 2014-06-26 |
20140178469 | STABLE BENZIMIDAZOLE FORMULATION - A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents. | 2014-06-26 |
20140178470 | DISPERSIBLE TABLET - The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt, for dispersion in water and administration via a tube to a patient with swallowing difficulties. | 2014-06-26 |
20140178471 | MULTI-LAYERED RELEASE FORMULATION - The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; Basic Butylated Methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, PEG and polyvinylacetate; or combinations thereof. | 2014-06-26 |
20140178472 | Methods of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 2014-06-26 |
20140178473 | SOLID DOSAGE FORM - There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided. | 2014-06-26 |
20140178474 | SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION - The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen. | 2014-06-26 |
20140178475 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 2014-06-26 |
20140178476 | Highly Efficient Delivery of a Large Therapeutic Mass Aerosol - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm | 2014-06-26 |
20140178477 | SOLID PREPARATION - The present invention provides a solid preparation formulation containing a poorly water-soluble agent having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, in which the saccharide/cellulose weight ratio exceeds 2 and the cellulose content is not less than 5 wt %. This formulation provides a composition that can be produced with direct granulation, yet which delivers stability during production and storage. | 2014-06-26 |
20140178478 | Immuno-Adjuvant Emulsion - The invention relates to an oil-in-water adjuvant emulsion which comprises at least:
| 2014-06-26 |
20140178479 | Concentrated Felbamate Formulations for Parenteral Administration - Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma. | 2014-06-26 |
20140178480 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS - Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive. | 2014-06-26 |
20140178481 | Water-In-Oil Type Emulsion Sunscreen Cosmetics - The present invention provides water-in-oil type emulsion sunscreen cosmetics that achieve an excellent UV blocking effect, and have excellent effects in the prevention and inhibition of discoloration (discoloration to red). The water-in-oil emulsion sunscreen cosmetic according to the present invention is characterized by comprising: (a) octocrylene; (b) hydrophobized zinc oxide; (c) cationic surfactant; and (d) silica. | 2014-06-26 |
20140178482 | METHOD OF PRODUCING VIRUS-LIKE PARTICLES OF PICORNAVIRUS USING A SMALL-UBIQUITIN-RELATED MODIFIER FUSION PROTEIN EXPRESSION SYSTEM - A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in | 2014-06-26 |
20140178483 | SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF - SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided. | 2014-06-26 |
20140178484 | MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION - A multi-particulate pharmaceutical composition suitable for administration in a sprinkle dosage form said particles being less than 2 mm in diameter and comprising
| 2014-06-26 |
20140178485 | ACTIVE AGENT MICROPARTICLES - The present invention concerns polymeric-enveloped microparticles including at least one HASE type acrylic copolymer, at least one solid-liquid phase change material with a phase transition temperature ranging from 20 to 90° C., and at least one active agent. In particular, the microparticles include at least one HASE type acrylic copolymer including at least one anionic monomer with a polymerizable vinyl group and a carboxyl group, at least one non-ionic hydrophobic monomer with a polymerizable vinyl group, and at least one alkoxylated associative macromonomer with a polymerizable vinyl group and a hydrophobic hydrocarbon chain. | 2014-06-26 |
20140178486 | CANCER TREATEMENTS - This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided. | 2014-06-26 |
20140178487 | CAMEL HUMP OIL - BASED HERBAL COMPOSITIONS AND METHOD OF MAKING THE SAME - The embodiments herein provide camel hump oil based herbal compositions and methods for preparing these compositions for treatment of a plurality of diseases such as dermatological conditions, musculoskeletal conditions and hair conditions. The embodiments herein also provide a method of extraction of camel hump oil from a camel hump and a method of de-odorizing the extracted camel hump. The camel hump-oil based herbal composition comprises camel hump oil, a herbal oil extract, a curing agent and a plurality of additives. The camel hump oil based composition is topically applied. | 2014-06-26 |
20140178488 | COMPOSITION AND METHOD TO IMPROVE BLOOD LIPID PROFILES AND OPTIONALLY REDUCE LOW DENSITY LIPOPROTEIN (LDL) PER-OXIDATION IN HUMANS - A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from | 2014-06-26 |
20140178489 | Low Flouride Crustacean Concentrated Hydrolysate Fraction Compositions - Fluorine being present in the exoskeleton of crustaceans, and especially krill represents a problem for using krill as a source for food, feed, food additives and/or feed additives. There has been developed a process for removing such fluorine from krill material by subjecting the krill to disintegration and to an enzymatic hydrolysis process prior to or simultaneously with a removal of the exoskeleton particles producing a fluorine-reduced product. Inherent in the disclosed process is the ability to process krill material with a high polar lipid content for producing superior quality, low fluorine, products suitable for the food and feed as well as the pharmaceutical, nutraceutical and cosmetic industry. | 2014-06-26 |
20140178490 | Mummified Mealy Bug Product and Method - A Biological Control Agent (BCA) system comprising processed parasitized mealybug mummies is disclosed. The processed and modified parasitized mealybug mummies are essentially devoid of their limbs and waxy covering. In the novel BCA system the modified parasitized mealybug mummies are processed in a manner that strips off their waxy covering and detaches their limbs without impacting on their viability as a host for parasitoid pupae. The modified parasitized mealybug mummies of the BCA system are encased in specially adapted packaging for delivering and distributing the modified parasitized mealybug mummies to plants with mealybug infestations. A method of preparing and storing the modified parasitized mealybug mummies as a BCA is also presented. | 2014-06-26 |
20140178491 | MULTIPLE SEPARATION FILTER AND ANTIOXIDIZING WATER PRODUCED USING THE SAME - Disclosed is a multiple separation filter including a microfiltration membrane, an active carbon-based filter and a ceramic filter stacked in order, wherein the active carbon-based filter is obtained by mixing active carbon with at least one selected from zeolite, gold, silver and a mixture thereof, treating the mixture with plasma gas of 60,000° C. to 70,000° C., and then quenching the mixture to −200° C. to −273° C. under vacuum, and the ceramic filter is obtained by quenching plasma gas generated by heating magnesium at 60,000° C. to 70,000° C. to −200° C. to −273° C. under vacuum. Disclosed also is antioxidant water obtained by using the multiple separation filter. The antioxidant water has a negative oxidation reduction potential. | 2014-06-26 |
20140178492 | BOWEL CLEANSING COMPOSITION - The invention provides compositions for rapid bowel cleansing comprising a water-soluble mixture of polyethylene glycol and sodium phosphate(s). The compositions are particularly useful for preparing the bowel prior to surgery or diagnostic procedures such as colonoscopies. The invention further comprises methods for cleansing the bowel using these compositions, and bowels cleansing kits comprising these compositions. | 2014-06-26 |
20140178493 | TANNIN FORMULATION FOR TREATING GASTROINTESTINAL SPASMS IN A SUBJECT HAVING CROHN'S DISEASE OR ULCERATIVE COLITIS - Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea. | 2014-06-26 |
20140178494 | METHODS OF TREATING GASTROINTESTINAL SPASMS IN A SUBJECT HAVING DIVERTICULITIS - Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea. | 2014-06-26 |
20140178495 | TANNIN FORMULATION FOR TREATING GASTROINTESTINAL SPASMS IN A SUBJECT HAVING DIVERTICULITIS - Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea. | 2014-06-26 |
20140178496 | ENDOSPORE COMPOSITIONS AND USES THEREOF - Provided herein in some embodiments is a composition that comprises (a) a nanoscale particle(s) or a microscale particle(s); and (b) a film-forming polymer. Also provided herein is a method for an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Further provided herein in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, wherein a method comprises applying to the skin or surface a composition, wherein the composition comprises (a) a nanoscale particle(s) or a microscale particle(s); and (b) a film-forming polymer. | 2014-06-26 |
20140178497 | THRUSH TREATMENT PASTE - A composition for treating hoof thrush and similar ailments in horses is composed of a blend of copper sulfate and chlorhexidine dispersed in a viscous carrier. Preferably, the copper sulfate makes up 20 to 45 percent by weight of the final product and the chlorhexidine compound accounts for 1 to 5 percent by weight. A viscous carrier constitutes the balance of the formulation. | 2014-06-26 |
20140178498 | METHOD FOR GENERATION OF NANOPARTICLES COMPOSITE FILMS AND FILMS MADE USING SUCH A METHOD - Proposed is a method for the production of at least one composite layer ( | 2014-06-26 |
20140178499 | COMPOSITION FOR PREVENTING AND HEALING OSTEONECROSIS OF THE JAW - A composition for preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005%-2.0% weight/volume (w/v) chlorine dioxide source, such as sodium chlorite, chlorite ion, stabilized chlorine dioxide or similar and may take the form of a paste, gel, rinse, spray, powder, varnish or similar. The prevention and treatment includes the application of the composition in the oral cavity and other body areas affected by osteonecrosis of the jaw. | 2014-06-26 |
20140178500 | METHODS OF TREATING OUTER EYE DISORDERS USING HIGH ORP ACID WATER AND COMPOSITIONS THEREOF - The present invention relates to a method of treating an outer eye disorder selected from a cataract, neovascularization, keratitis, epithelium deficiency, or chronic opacity, by administering to the eye a composition comprising acidic electrolytic water. The present invention also relates to a stable acidic electrolyzed oxidizing water characterized by low conductivity, the presence of dissolved chlorine gas (Cl | 2014-06-26 |
20140178501 | BIOCIDES AND APPARATUS - A method for controlling microbial or biofilm growth in a medium includes mixing ammonium carbamate or ammonium sulfamate with an aqueous solution of a hypochlorite oxidant to form a biocide having a pH between 9.0 and 11.5, the molar ratio of the ammonium carbamate or ammonium sulfamate to the hypochlorite being at least 1:1; and then applying the biocide to the medium. | 2014-06-26 |
20140178502 | METHOD FOR PREVENTING AND TREATING MASTITIS - When a rock powder which contains silicic acid and aluminum oxide as active ingredients is given to livestock animals, nitrogen compounds including ammonia nitrogen and nitrate nitrogen generated in the body of the livestock animals can be chemically adsorbed by aluminum oxide and silicic acid, whereby the over-absorption of the nitrogen compounds through the digestive tract can be suppressed. At the same time, minor elements contained in the rock powder act to fully elicit the activity of a nutritional component capable of suppressing mastitis, e.g., vitamin A, vitamin E, copper, zinc and manganese obtained from the feed. In this manner, the onset of mastitis can be suppressed in a nutritional manner, and a therapeutic effect can be achieved on mastitis that has already been developed. | 2014-06-26 |